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Abstract 
Background and purpose 
To evaluate the short-term outcome of recombinant human Erythropoietin (EPO) therapy in 
rats with spinal cord injury (SCI) using manganese enhanced magnetic resonance imaging 
(MEMRI). 
 
Methods 
Rats were divided in an EPO and a control group. Laminectomy at Th11 was performed, 
followed by SCI. MnCl2 was applied into the cisterna magna and functional recovery was 
examined after injury using BBB-scoring. Then, rats were euthanized and the spinal cord 
was extracted for MEMRI. Finally, histological analysis was performed and correlated with 
MEMRI. 
 
Results 
EPO-treated animals showed significantly better functional recovery (p = 0.008, r = 0.62) and 
higher mean signal-to-noise (SNR) in MEMRI compared to controls for slices 10-13 (p = 
0.017, R² = 0.31) at the height of the lesion epicenter. Functional recovery correlated 
significantly with higher SNR values, determined using the mean SNR between slices 10-13 
(p = 0.047, R² = 0.36). In this region, histology revealed a significantly decreased number of 
microglia cells and apoptosis in EPO-treated animals. 
 
Conclusion 
MEMRI successfully depicts the therapeutic effect of EPO in early spinal cord injury that 
leads to a significant recovery in rats, a significantly reduced immune response and 
significantly reduced number of apoptotic cells at the height of the lesion epicenter. 
 
Introduction 
Spinal cord injury 
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Injury to the spinal cord often results in a devastating condition with the severe loss of motor, 
sensory and autonomic functions. Substantial efforts have been made to obtain an effective 
therapy that could at least attenuate the outcome of spinal cord injury (SCI). Although some 
therapeutical approaches look promising , generally most of them prove to be ineffective. It is 
widely accepted, that any intervention to improve the outcome of SCI should be administered 
early after the primary injury in order to prevent secondary damage. An increasing amount of 
evidence indicates that erythropoietin (EPO) is an effective neuroprotective substance . 
Recombinant human erythropoietin (EPO) is routinely used in patients with anaemia of renal 
or tumor origin, but additionally, it has been reported to prevent secondary neuronal damage 
after experimental spinal cord injury  and stroke . The mechanism of neuroprotective action 
of EPO appears to be based on several components: 1) an anti-ischemic effect, 2) anti-
inflammatory capacity that reduces the extent of apoptosis, infiltration of proinflammatory 
cytokines and leukocytes and 3) neoangiogenesis promoted by endothelial cell proliferation . 
Apart from its neuroprotective effect, EPO has been shown to promote axonal regeneration . 
There are several morphological and functional approaches to assess the extent of tissue 
damage after SCI and the amount of spared tissue following application of various 
therapeutic strategies. Recently, Manganese-Enhanced Magnetic Resonance Imaging 
(MEMRI) has been introduced in the arsenal of functional evaluation tests following 
experimental spinal cord injury in animal models .  
 
Manganese-enhanced magnetic resonance imaging 
Manganese was initially used as a radioactive tracer molecule in the central nervous system 
(CNS)  and first introduced as a possible in vivo MRI contrast agent in 1998 . Mn2+, analogue 
to Ca2+, is taken up into neurons by voltage-gated Ca2+-channels  and it is further transported 
along the axon . Alternatively, Mn2+ is bound to transferrin and transported into the cell by 
endocytosis using the transferrin receptor . The visualization of manganese is based on a 
strong contrast enhancement of Mn2+-ions in T1-weighted MRI, related to the shortening of 
the water spin-lattice relaxation time constant (T1) . Therefore, manganese acts as an 
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excellent contrast agent for neuronal tissue when being imported and processed into the cell 
. In general, the signal enhancement of the spinal cord in rats can be achieved after injecting 
Mn2+ into the cisterna magna . 
In a previous study, we have shown a close correlation of MEMRI results with locomotion 
testing and histology in rats undergoing SCI . Therefore, we hypothesize that MEMRI is an 
adequate imaging-based evaluation method of therapy outcome in spinal cord injury. The 
aim of the present study is to determine the short-term therapeutic effect of EPO after a 
spinal cord contusion injury in rats and compare MEMRI data with the results of locomotor 
tests and histological analysis. 
Materials and Methods 
Animal preparation 
Experiments were carried out on 18 male Sprague-Dawley rats weighing 300-350 g (Animal 
Research Laboratories, Himberg, Austria) and lasted for a period of 3 days. The 
experimental protocol was approved in advance by the Animal Protocol Review Board of the 
City Government of Vienna. All procedures were carried out in full accord with the Helsinki 
Declaration on Animal Rights and the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health (publication NIH 86-23, revised 1985). Rats were 
anesthetized by the intraperitoneal administration of a combination of ketamine hydrochloride 
+ xylazine (ketamine hydrochloride: 90 mg/kg body weight, Ketavet, Pharmacia & Upjohn 
Co.; xylazine: 5 mg/kg body weight, Rompun, Bayer Co.). Adequate care was taken in all 
cases to minimize the levels of pain and discomfort during and after the operation. Core body 
temperature was measured with a rectal probe and maintained at 37°C. All rats underwent a 
laminectomy at the 11th thoracic vertebra (TH11) followed by a contusion injury using the 
Infinite Horizon Impactor (Precision Systems and Instrumentation, LLC, Lexington, KY, 
U.S.A.). A definite impact force of 150 kdyn was used for the SCI (n = 18). Afterwards, a 
suture of deeper tissue was performed by respecting the anatomical layers of fasciae and 
muscles, followed by a cutaneous suture with simple interrupted stitches. Postoperative 
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treatment included subcutaneous injections of 10 ml Ringer’s solution and antibiotics (Peni-
Strepto, 50,000 IU, Virbac Laboratory, Carros, France) after surgery and then for 2 days. 
After surgery, MnCl2-injections were performed. Rats were fixed having their heads in a 90° 
flexed position and 80 µl of 0.8 mM MnCl2 was administered via the atlanto-occipital 
membrane employing a 27-gauge needle. Animals in the EPO group (n=9) received 1000 
IU/kg EPO intravenously one hour after the injury, whereas animals in the control group 
(n=9) received identical volumes of physiological saline. 
At the end of the survival period, rats were re-anaesthetized as described above. The 
animals were first transcardially perfused with physiological saline containing 1000 I.E. 
heparin (EBEWE Pharma, Unterach, Austria) followed by phosphate-buffered 
paraformaldehyde (4%, pH=7.4, VWR International, Vienna, Austria). The vertebral column 
was extracted postmortem from the 1st cervical to the 2nd vertebra and immersion fixed 
overnight. After fixation, samples were stored in phosphor-buffered sucrose containing 
0.01% Na-azide until processed for MRI analysis. 
 
Locomotion Testing 
The tester was blinded towards the group membership of the animals before surgery and 3 
days after injury. Tests were performed using the previously described BBB-scoring, a 
locomotor rating scale originally introduced by Basso, Beattie and Bresnahan (BBB score) . 
In this test, the hind limbs are examined separately on a scale from 0 to 21. The value 0 
corresponds to total paraplegia of the extremity whereas the value 21 indicates fully intact 
locomotion. All rats were euthanized after locomotion testing on day 3. One rat (EPO-group) 
was excluded from functional recovery examinations due to testing difficulties. 
 
MRI 
For the MRI examinations, the excised spinal cords were stored in tubes containing 
formaldehyde for fixation (15 ml capacity, 23 mm diameter). MRI was performed using a 
clinical 1.5-T-scanner (Siemens Symphony, Erlangen, Germany) with a custom-made animal 
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volume resonator employing a T1-weighted 3DFLASH imaging pulse sequence (TR/Te 
14.0/5.22 milliseconds, voxel size in-plane 0.15 x 0.15 mm, 16 averages, flip-angle 30°, 28 
partitions, partition thickness: 0.5 mm, field of vision (FOV) 80 mm, matrix size 512 x 512, 
scan time 30 minutes). Imaging was performed perpendicular to the longitudinal axis of the 
spinal cord. 
Image evaluation was perfomed using Syngo Via25, included in the scanner software 
package (Siemens, Erlangen, Germany). The spinal cord was divided into 19 axial slices and 
slice 10 was placed at the height of the epicenter. Signal-to-noise was calculated on a region 
of interest-based method (n = 18). A region of interest was placed outside the animal 
contours for noise measurement. By taking the average of the most proximal and most 
distant noise measure, the signal to noise ratio has been calculated. The 3D MRI 
reconstruction was created using Fovia Software (Fovia Inc., Palo Alto, California, USA). 
 
Histological assessment 
After completing the MEMRI analysis of the samples, the spinal cords were carefully 
removed from the vertebral canal and immersed in 30% sucrose (in phosphor buffered 
sucrose). In both the treatment and control groups, five animals were selected for evaluation 
that had the most uniform BBB values (i.e. close to the mean BBB value in each group). 25 
μm transverse parallel sections were cut on a cryostat (Leica CM 1850, Leica GmbH, 
Germany) and mounted onto gelatin-coated glass slides. The extent of apoptosis was 
assessed immunohistochemically using the ApopTag Peroxidase In Situ Apoptosis Detection 
Kit S7100 (Merck Millipore Co, Billerica, MA, USA). This method labels the nucleosome-
sized DNA fragments by tailing the 3'-OH ends of the fragments with digoxigenin 
deoxyribonucleotide triphosphate (dUTP) using terminal deoxynucleotidyl transferase (TdT). 
TdT catalyzes a template-independent addition of nucleotide triphosphates to 3'-OH ends of 
double-stranded or single-stranded DNA. Endogenous peroxidase was inactivated by 
immersing the sections in 3% hydrogen peroxide. DNA fragments were then tailed with 
digoxigenin-dUTP by TdT, and incubated with an antidigoxigenin antibody conjugated with 
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peroxidase for 30 min at room temperature. The reaction was visualized using 
diaminobenzidine (DAB) and the sections were counterstained with methyl-green (VWR, 
Debrecen, Hungary). 
Square areas of 250 x 250 µm in the ventral horns and in the ventral part of the dorsal 
funiculus were digitally analyzed at the level of the epicenter and 0.5, 1.0 and 1.5 mm rostral 
and caudal to that. The apoptotic index (AI), defined as the ratio of the total counted 
Apoptag-positive nuclei and the number of methyl-green-positive cells multiplied by 100 was 
determined. Thus, the AI reflects the ratio of the apoptotic cells in the total number of cells in 
a given area of a spinal cord section.  
Lectin histochemistry was performed on paralled cryostat section using biotinylated Griffonia 
(Bandeira) simplicifolia lectin B4 (GSA-B4, 1:200, overnight, Vector Labs, Burlingame, CA, 
USA). Lectin binding was visualised through the use of streptavidin Alexa Fluor 546 
conjugate (1:400, for 2h, Invitrogen). Fluorescent signals were detected in an Olympus FX50 
epifluorescence microscope equipped with a DP70 digital camera (Olympus Ltd, Tokyo, 
Japan). Square areas of 200 x 200 µm in the ventral horns and in the ventral part of the 
dorsal funiculus were digitally analyzed at the level of the epicenter and 0.5, 1.0 and 1.5 mm 
rostral and caudal to the epicenter. Microglial densities indicated by the GSA-B4 reaction 
were determined by using the Image-J analysis program (NIH). 
 
Statistical Analysis 
Statistics were performed using IBM SPSS Statistics Version 20 . We used an alpha level of 
0.05 for all statistical tests. Linear regression of SNR (for all slices separately) and BBB-
scoring was used with the group as independent variable to test the hypotheses regarding 
the difference between EPO and control group in MRI signal. To correlate MRI signal and 
BBB-scoring, Kendall’s tau-b test was utilized. Simple student’s t-test was used to analyze 
group differences of microglia cells and apoptosis index. 
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Results 
MEMRI 
EPO-treated animals showed higher SNR for slices 10-12 (slice 10: p = 0.031, R² = 0.26; 
slice 11: p = 0.013, R² = 0.33; slice 12: p = 0.028, R² = 0.27) located at the lesion epicenter. 
Slice 13 trended towards significance (p = 0.08, R² = 0.126). Also mean SNR of slices 10-13 
was significantly increased in EPO-treated animals (p = 0.017, R² = 0.31). A higher BBB-
score correlated significantly with higher SNR values, determined using the mean SNR 
between slices 10-13 (p = 0.047, R² = 0.36). The T1-signal of EPO-treated rats was overall 
increased compared to controls. The highest mean difference was noticed at slice 10 (~2.4 
a.u.), which represented the lesion epicenter. As shown in Figure 1 and seen in every 
sample, the signal intensity continuously drops with a small slope from slice 1 to slice 7. 
Then, a higher slope is noticed between slice 7 and 11, representing the area around the 
lesion epicenter. Finally, the curve regains its original slope from the beginning, shown 
between slice 11 and 19 on the level of unenhanced spinal cord tissue as it has been 
reported earlier .  
 
Functional evaluation 
The results revealed a significant difference of BBB-scores between controls and treated 
animals (p = 0.008, r = 0.62). Boxplot of distribution is shown in Figure 2. The physical 
examinations of the rats as quantified using the BBB-score showed significantly better 
outcome in the EPO group, however, with a higher variability represented by a more 
expanded distribution in the box plot graph (Figure 2). In contrast, the BBB-scores of the 
control group were in a more homogeneous, narrow range. 
 
Histo-morphological findings 
Due to the short survival time, no proper cystic cavities were formed. Therefore, the 
morphological analysis focused on the differences in the extent of apoptosis and microglial 
activity in the injured cord.  
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Significantly more apoptotic cells were found in the spinal cords of control animals at the 
epicenter and cranial to the lesion site at all three sampling sites (left and right ventral horns 
and ventral portion of the dorsal funiculus, Figure 3). The difference in AI between control 
and EPO-treated animals was negligible 1.5 mm cranial and approximately 1 mm caudal to 
the epicenter. However, the greatest difference between the control and treated groups were 
found in the region of the dorsal funiculus, where the main impact was implied to the cord. 
Spinal cord segments affected in this region were densely populated by round, amoeboid-like 
microglial cells, both in the control and EPO-treated animals. However, microglial density 
was found to be upregulated to a much greater extent in the spinal cords of control animals 
(Figure 4). Considerable microglial activation was observed in both control and EPO-treated 
cords 2 mm cranial and caudal to the epicenter (Figure 4). It is noted that microglial densities 
appeared to be moderate in the cords of EPO-treated animals caudal to the epicenter. 
Microglial densities at the level of epicenter were not determined due to the very high 
background noise.  
Discussion 
Findings of previous experimental in vitro and in vivo studies  suggest that 1) manganese 
preferably accumulates in healthy neuronal cells/axons, 2) damaged neurons show less 
contrast enhancement as a sign of less import of manganese into the cell and 3) locomotor 
assessment rating, histology results and Mn2+ concentrations correlate with MEMRI signal 
measurements. Taking the above listed arguments as basis for our current study, we 
hypothesized that MEMRI is an adequate tool for the monitoring of therapeutic approaches in 
SCI.  
 
EPO treatment reduces microglial reactions and apoptosis 
Visualization of apoptotic cells in the injured cord showed significantly reduced numbers of 
apoptotic cells in EPO-treated animals compared to controls (Figure 3). The significant 
difference found in the dorsal funiculus rostral to the epicenter is thought to appear due to the 
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degeneration of the ascending fibers in control animals. Microglia density measurements 
paralleled these results as EPO-treated animals had decreased microgliosis cranial and 
distal to the lesion epicenter than control animals, however, microglia densities were reduced 
all over the EPO-treated cords (Figure 4). 
As reported earlier, the initial inflammation and later formed glial scar are perhaps the most 
important inhibitors of neural regeneration in spinal cord injury . The invasion of microglia 
cells and leucocytes to the injury location is supposed to be an amplifier of inflammation 
since they themselves release proinflammatory/proapoptotic cytokines in the early spinal 
cord trauma . Therefore, the number of microglia cells serves as an indicator for immune 
response and future outcome. In the very early phase of spinal cord injury, the initial 
homoeostasis of cytokines is disrupted by the trauma, followed by the upregulation of 
proinflammatory mediators, IL-1alpha/beta, IL-6 and TNF-alpha . The release of these 
cytokines occurs 6 to 12 hours after the trauma and peaks at day four . All of these mediators 
are known to have cytotoxic abilities and may induce apoptosis. The molecular effects of 
EPO in spinal cord injury are yet not fully understood. As reported earlier, the binding of EPO 
to the EPO-R receptor on immune cells enhances the release of cell survival protein BcL-xL 
via JAK2/STAT5- and Nf-kb pathways  and therefore leads to reduced cell apoptosis. 
Upregulation of BcL-xL via JAK2/STAT3 and PI3K/AKT pathway activation by EPO may also 
have a neuroprotective effect on damaged neurons as it has been demonstrated for retinal 
neuron cells . Both the limited extent of apoptosis and reduced microglial activation in EPO 
treated animals is in line with other reports .  
A reduced number of apoptotic cells can clearly be considered to be a result of the 
neuroprotective effect of EPO. Also, the reduced microglial activity in our samples is another 
sign of an indirect neuroprotective effect of EPO as robust microglial invasion eventually 
results in engulfing of degenerating neurons. Although this short term study did not allow for 
the determination of the extent of regeneration in EPO-treated animals, it can be argued that 
limited microglial reactions induce less astroglial scarring and thus contribute to more 
extensive axonal regeneration in the EPO-treated spinal cords . Thus, together with earlier 
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reports , our results support the dual function of EPO therapy promoting both regeneration 
and neuroprotection in the CNS.  
  
MEMRI and functional recovery 
We found a significantly increased overall T1-signal in EPO-treated animals (Figure 1). The 
SNR values around slice 10 - the impact epicenter - reveal the highest differences in T1 
signal (~2.4 a.u.) thus indicating that the highest difference in healthy neurons between the 
two groups can be found there. It was hypothesized that MEMRI will depict a loss of T1w 
contrast that is partially reversible under EPO therapy in spinal cord injury. In accordance to 
this hypothesis, overall higher T1 signal in EPO treated animals indicates a higher number of 
healthy neurons which are able to uptake manganese as a sign of vital function. 
Substantiating this observation, BBB-score and SNR showed good correlation indicating that 
a higher SNR between slices 10-13 corresponded to a higher physical examination value, 
independent of the group. Comparing the physical examinations of both groups, we assume, 
that EPO therapy significantly increases the functional recovery in rats after 3 days after 
injury and that there are individual differences in response to EPO therapy which explains the 
broadening of the distribution. In summary, our findings in histology, physical examinations 
and imaging-based evaluation support a neuroprotective and also secondary regenerative 
effect of EPO in early spinal cord injury. Moreover, MEMRI is an adequate method for the 
EPO therapy evaluation as it indicates the amount of damaged neurons in a semi-
quantitative approach. 
An interesting, yet unsolved question is why a reduced manganese contrast enhancement is 
also seen above the lesion epicenter (Figure 1, slices 6-9, this result was already found in a 
previous study ). As the loss of a neuron is also accompanied by the loss of its axon and its 
integration in a complex neuronal network, it seems to be plausible that the injury also affects 
neuronal cells on other levels. A suitable explanation for this effect is that the missing 
contrast enhancement above the epicenter results from the complete disconnection of axons 
at the height of the traumatic injury which then leads to a decreased uptake of manganese 
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above the lesion. This thesis also supports the finding that the signal intensity below the 
epicenter corresponds to that of an unenhanced spinal cord, caused by the irrevocable 
destruction of axons. 
An uncertain factor is the potential manganese uptake by microglial cells. There is evidence 
that microglial cells have voltage-gated Ca2+ receptors at the cell surface albeit they seem to 
play a less important role under normal conditions . Thus, microglial cells may take up 
manganese, similar to the uptake in neuronal tissue. In this case, the loss of signal due to 
neuronal damage could be counteracted by the increase of microglia invasion at the injury 
site. However, the calcium current in microglial cells is small and not observed under 
physiological conditions  and thus presumably contributes, if at all, to a minor extent to 
MEMRI. 
The histology results correlated well to the findings obtained by MEMRI. As shown in Figure 
5, the significantly decreased apoptosis and immune reaction in the EPO group 
corresponded to the increased signal intensity. We believe, that the reduced amount of 
apoptotic cells is the main reason for the increased T1-signal intensity in EPO treated 
animals as it analogously has been already reported earlier . 
One limitation of the study is that the physical examination was performed in vivo, whereas 
MRI quantification was performed ex vivo, analogously to earlier reports. Thus, after the 
extraction and fixation of the spine, Mn2+ may have diffused from the neuronal tissue into the 
surrounding tissue. We know from earlier studies , that Mn2+ is preferably taken up by healthy 
neurons but this diffusion process may decrease the initial in vivo difference in signal 
intensity to the disadvantage of treated animals. However, we did not observe a signal 
increase in the surrounding tissue and found a significant difference between the two groups 
post mortem. We cannot exclude a diffuse loss of Mn2+ and assume that the group difference 
may be even larger if the experiment is performed in vivo.    
Summary and Conclusion 
We investigated rats with spinal cord injury three days after injury and therefore, our study 
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serves as a model for the initial stage of the trauma. In this short term evaluation, we show 
that the intravenous application of EPO leads to a significant better recovery after SCI in rats 
at 3 days and that MEMRI may serve as a semi-quantitative imaging approach to monitor the 
response of damaged neuronal tissue to EPO therapy.  
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Figure 1 (in color):  
Upper part: Postmortem T1-weighted manganese enhanced magnetic resonance imaging of 
an extracted spinal cord (rat). The spinal cord has been stored and measured in a tube 
containing formaldehyde. a) Homogeneous contrast uptake is seen above the lesion 
epicenter (b). Below, c) a decrease of signal intensity is observed. Lower part: SNR within 
the spinal cord in the two groups. Slices are running from cranial (1) to caudal (19), the lesion 
epicenter was located at slice number 10. Error bars represent the standard deviation within 
both groups. The equivalent position of slice 1, 10 and 19 in the MEMRI is shown (see red 
arrows). Asterisks indicate significantly increased signal intensity in the EPO group 
compared to controls for slices 10 (p= 0.031), 11 (p=0.013) and 12 (p=0.028). 
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Figure 2:  
Boxplot distribution of physical examination (controls vs. EPO group on x-axis) using the 
BBB-score (y-axis); n = 17. The BBB-scores of both hind-limbs have been summed to one 
value per animal. The EPO treated animals show significantly higher values as a sign of 
therapy response (p = 0.008, r = 0.62) despite two overlapping outliers lying at value 8 in the 
control group.  
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Figure 3: 
Immunohistological staining of apoptotic cells in the dorsal funiculus and in the left and right 
ventral horns of the spinal cord. Figures a1-a3 represent the EPO-treated group, b1-b3 the 
control group. Panels a and b show apoptotic cells indicated by their dark nuclei (arrows in 
a1). It is noted that fewer apoptotic cells occur in the spinal cords of rats treated with EPO 
(a1- a3) compared to controls (b1-b3). Graphs show the apoptosis index values at various 
levels cranial and caudal to the injury. Asterisks indicate significant difference between the 
EPO-treated and control group, error bars indicate the standard deviation. Significant 
differences are found only cranial to the epicenter (*).Simple t-test, p≤ 0.05. Scale bar in a1-
b3 = 50 µm. 
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Figure 4(in color): 
Microglia density measurements in left ventral horn (a versus d), the dorsal funiculus (b 
versus e) and right ventral horn (c versus f) of the spinal cord. The amount of microglia cells 
was significantly reduced in rats treated with EPO (a-c) cranial as well as distal of the lesion 
epicenter when compared to controls (d-f). The distance from the epicenter is given above 
the images. EPO: Erythropoietin group (a-c); control group (d-f). The dashed white lines 
indicate the border between grey (located within the lines) and white matter (located outside 
the lines). 
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Figure 5(in color): 
3D MRI reconstruction of the spinal cord of a typical sample for the summarized presentation 
of findings. 
A: Arrow: location of the injury which corresponds to slice 10 in every sample. The white 
rectangle indicates the magnified area of interest in the spinal cord. The cranial parts of the 
spinal cord show a clear, homogeneous uptake of manganese with high signal intensity 
(yellow color). Below the impact epicenter, a strongly reduced uptake of manganese is 
noticed (red color). Notably, there are centrally located areas below the impact zone which 
show an intermediate uptake of manganese (blue color).  
B: To visualize the summarized changes of histological analysis, distances in µm from the 
epicenter are shown (0µm and 2500µm, respectively). In the EPO group, there is a 
significantly decreased amount of apoptotic cells noticed (a)) as well as a significantly 
decreased amount of microglia cells corresponding to the reduced immune response (b)). 
C: To demonstrate the correlating changes in signal intensity, distances in µm from the 
epicenter are shown. From left to right, slices 9-13 are plotted with white lines. Significantly 
increased signal intensity in the EPO group compared to controls was noticed for single 
slices 10 (p = 0.031), 11 (p = 0.013) and 12 (p = 0.028), indicated by asterisks, and also for 
the overall mean signal of slices 10-13 (p = 0.017) (c)). 
